What is HC Wainwright’s Estimate for VTYX Q2 Earnings?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – Stock analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Ventyx Biosciences in a research note issued on Wednesday, November 5th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.56) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Ventyx Biosciences’ Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.35) EPS, FY2027 earnings at ($2.24) EPS, FY2028 earnings at ($1.99) EPS and FY2029 earnings at ($1.57) EPS.

A number of other research analysts also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Oppenheimer upped their price target on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a report on Monday, October 27th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $16.00.

Ventyx Biosciences Stock Down 11.1%

Shares of VTYX traded down $1.03 during mid-day trading on Friday, hitting $8.23. 761,782 shares of the company’s stock were exchanged, compared to its average volume of 2,124,263. The firm has a market cap of $587.10 million, a price-to-earnings ratio of -4.94 and a beta of 1.23. The stock’s 50-day simple moving average is $4.08 and its 200-day simple moving average is $2.85. Ventyx Biosciences has a 52 week low of $0.78 and a 52 week high of $9.50.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.13.

Institutional Investors Weigh In On Ventyx Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. CWM LLC increased its position in Ventyx Biosciences by 7.6% during the 2nd quarter. CWM LLC now owns 57,145 shares of the company’s stock worth $122,000 after purchasing an additional 4,057 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Ventyx Biosciences by 21.1% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company’s stock worth $62,000 after buying an additional 5,174 shares during the last quarter. Hudson Bay Capital Management LP bought a new stake in shares of Ventyx Biosciences during the second quarter worth $34,000. Pallas Capital Advisors LLC acquired a new position in shares of Ventyx Biosciences during the second quarter worth $38,000. Finally, Engineers Gate Manager LP bought a new position in shares of Ventyx Biosciences in the 2nd quarter valued at $42,000. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.